While in 43 ERBB2-negative breast cancers SRCIN1 CN was never altered, in ERBB2-amplified tumours26, 56% of the specimens were amplified for SRCIN1 (Fig. 2c). This evidence concerns the gene ERBB2 and breast carcinoma.